Biopharmaceuticals are what are manufactured at the end of a very long, arduous processes are biotechnology firms. These are solutions, or compositions of protein, including antibodies and nucleic acids like antisense oligonucleotides, RNA and DNA, and are acquired by a non-engineered, native or biological source or via direct extraction.
They are required for therapeutic and diagnostic purposes. Usually, the preferred means for making these biopharmaceutical products are the actual life forms. And that the products made using small molecules are considered to be biopharmaceuticals.
Many Indian pharmaceuticals have been trying to innovate, and at the same time, is becoming the main destination for offshore R&D functions, and many of the big names in pharmaceuticals are doing just that so that they reduce drug development costs and that includes biopharmaceuticals. So, most of the success of the Bio-Pharmaceuticals Industry In India has come from this.
It addresses the needs of or is used in the treatment of conditions like cancers, arthritis, dissolving cholesterols and increasing the blood count or purifying it.
In terms of volume produced, India addresses over 50% of the requirement for pharmaceutical products globally, many of which are required in biotechnological applications. So far, this has built up this market to reach a value of INR 2,891.70 Bn in FY 2023. Bio-pharmaceuticals also exhibited a CAGR of ~31.7%, out of all biotechnology segments.
What gave that much-needed boost were the 46 new mergers and acquisitions that took place throughout 2017, most of this was done by players in the Indian biopharmaceutical market and was valued at over INR 94.77 Bn. Adding to that is the Indian government initiative for managing online pharmacies by implementing an electronic platform for the same, and along with that there is also the Pharma Vision 2020 program too – all of which is set to help India emerge as a biopharmaceuticals big-wig.
Our related post:
Top Trends in The Bio-Pharmaceuticals Industry in IndiaWhat’s driving the Bio-pharmaceuticals industry in India?
They are required for therapeutic and diagnostic purposes. Usually, the preferred means for making these biopharmaceutical products are the actual life forms. And that the products made using small molecules are considered to be biopharmaceuticals.
Many Indian pharmaceuticals have been trying to innovate, and at the same time, is becoming the main destination for offshore R&D functions, and many of the big names in pharmaceuticals are doing just that so that they reduce drug development costs and that includes biopharmaceuticals. So, most of the success of the Bio-Pharmaceuticals Industry In India has come from this.
It addresses the needs of or is used in the treatment of conditions like cancers, arthritis, dissolving cholesterols and increasing the blood count or purifying it.
In terms of volume produced, India addresses over 50% of the requirement for pharmaceutical products globally, many of which are required in biotechnological applications. So far, this has built up this market to reach a value of INR 2,891.70 Bn in FY 2023. Bio-pharmaceuticals also exhibited a CAGR of ~31.7%, out of all biotechnology segments.
What gave that much-needed boost were the 46 new mergers and acquisitions that took place throughout 2017, most of this was done by players in the Indian biopharmaceutical market and was valued at over INR 94.77 Bn. Adding to that is the Indian government initiative for managing online pharmacies by implementing an electronic platform for the same, and along with that there is also the Pharma Vision 2020 program too – all of which is set to help India emerge as a biopharmaceuticals big-wig.
Our related post:
Top Trends in The Bio-Pharmaceuticals Industry in IndiaWhat’s driving the Bio-pharmaceuticals industry in India?
No comments:
Post a Comment